ESR1 and breast cancer: Although the evidence currently indicates that extending AI-based treatment beyond 5 years does not reduce late recurrence risk in an unselected population of patients with ER+ BC [45–47], subset analyses indicated that patients with ER+/PgR-positive, node-positive disease might benefit from extended AI-based treatment.